Diagnostic use of nuclear β-catenin expression for the assessment of endometrial stromal tumors

Modern Pathology

Volumn 21, Issue 6, 2008, Pages 756-763

  Jung, Chan Kwon ^a   Jung, Ji Han ^a   Lee, Ahwon ^a   Lee, Youn Soo ^a   Choi, Yeong Jin ^a   Yoon, Seung Kew ^a   Lee, Kyo Young ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

catenin; CD10; Endometrial stromal tumor; Immunohistochemistry

Indexed keywords

BETA CATENIN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; GLYCOGEN SYNTHASE KINASE 3BETA;

ARTICLE; CANCER DIAGNOSIS; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DNA SEQUENCE; ENDOMETRIAL STROMAL TUMOR; ENDOMETRIUM SARCOMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; UTERINE CELLULAR LEIOMYOMATA; UTERUS MYOMA;

BASE SEQUENCE; BETA CATENIN; CELL NUCLEUS; DIAGNOSIS, DIFFERENTIAL; ENDOMETRIAL STROMAL TUMORS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LEIOMYOMA; MOLECULAR SEQUENCE DATA; MUTATION; NEPRILYSIN; POLYMERASE CHAIN REACTION; SARCOMA, ENDOMETRIAL STROMAL; TUMOR MARKERS, BIOLOGICAL;

EID: 44349189788     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2008.53     Document Type: Article

References (26)

1. Conacci-Sorrell M, Zhurinsky J, Ben-Ze'ev A. The cadherin-catenin adhesion system in signaling and cancer. J Clin Pathol 2002;109:987-991.
2. Polakis P. Wnt signaling and cancer. Genes Dev 2000;14:1837-1851.
3. Ng TL, Gown AM, Barry TS, et al. Nuclear beta-catenin in mesenchymal tumors. Mod Pathol 2005;18:68-74.
4. Haydon RC, Deyrup A, Ishikawa A, et al. Cytoplasmic and/or nuclear accumulation of the beta-catenin protein is a frequent event in human osteosarcoma. Int J Cancer 2002;102:338-342.
5. Sakamoto A, Oda Y, Adachi T, et al. Beta-catenin accumulation and gene mutation in exon 3 in dedifferentiated liposarcoma and malignant fibrous histiocytoma. Arch Pathol Lab Med 2002;126:1071-1078.
6. Bhattacharya B, Dilworth HP, Iacobuzio-Donahue C, et al. Nuclear beta-catenin expression distinguishes deep fibromatosis from other benign and malignant fibroblastic and myofibroblastic lesions. Am J Surg Pathol 2005;29:653-659.
7. Montgomery E, Torbenson MS, Kaushal M, et al. Beta-catenin immunohistochemistry separates mesenteric fibromatosis from gastrointestinal stromal tumor and sclerosing mesenteritis. Am J Surg Pathol 2002;26:1296-1301.
8. Hrzenjak A, Tippl M, Kremser ML, et al. Inverse correlation of secreted frizzled-related protein 4 and beta-catenin expression in endometrial stromal sarcomas. J Pathol 2004;204:19-27.
9. Chu PG, Arber DA, Weiss LM, et al. Utility of CD10 in distinguishing between endometrial stromal sarcoma and uterine smooth muscle tumors: an immunohistochemical comparison of 34 cases. Mod Pathol 2001;14:465-471.
10. McCluggage WG, Sumathi VP, Maxwell P. CD10 is a sensitive and diagnostically useful immunohistochemical marker of normal endometrial stroma and of endometrial stromal neoplasms. Histopathology 2001;39:273-278.
11. Toki T, Shimizu M, Takagi Y, et al. CD10 is a marker for normal and neoplastic endometrial stromal cells. Int J Gynecol Pathol 2002;21:41-47.
12. Tavassoli FA, Devilee P. World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of the Breast and Female Genital Organs. IARC Press: Lyon, France, 2003.
13. Saegusa M, Okayasu I. Frequent nuclear beta-catenin accumulation and associated mutations in endometrioid-type endometrial and ovarian carcinomas with squamous differentiation. J Pathol 2001;194:59-67.
14. Franquemont DW, Frierson Jr HF, Mills SE. An immunohistochemical study of normal endometrial stroma and endometrial stromal neoplasms. Evidence for smooth muscle differentiation. Am J Surg Pathol 1991;15:861-870.
15. Sutton GP, Stehman FB, Michael H, et al. Estrogen and progesterone receptors in uterine sarcomas. Obstet Gynecol 1986;68:709-714.
16. Navarro D, Cabrera JJ, Leon L, et al. Endometrial stromal sarcoma expression of estrogen receptors, progesterone receptors and estrogen-induced srp27 (24 K) suggests hormone responsiveness. J Steroid Biochem Mol Biol 1992;41:589-596.
17. Samowitz WS, Powers MD, Spirio LN, et al. Beta-catenin mutations are more frequent in small colorectal adenomas than in larger adenomas and invasive carcinomas. Cancer Res 1999;59:1442-1444.
18. Iwao K, Nakamori S, Kameyama M, et al. Activation of the beta-catenin gene by interstitial deletions involving exon 3 in primary colorectal carcinomas without adenomatous polyposis coli mutations. Cancer Res 1998;58:1021-1026.
19. Fukuchi T, Sakamoto M, Tsuda H, et al. Beta-catenin mutation in carcinoma of the uterine endometrium. Cancer Res 1998;58:3526-3528.
20. Palacios J, Gamallo C. Mutations in the beta-catenin gene (CTNNB1) in endometrioid ovarian carcinomas. Cancer Res 1998;58:1344-1347.
21. Rashid A, Gao YT, Bhakta S, et al. Beta-catenin mutations in biliary tract cancers: a population-based study in China. Cancer Res 2001;61:3406-3409.
22. Voeller HJ, Truica CI, Gelmann EP. Beta-catenin mutations in human prostate cancer. Cancer Res 1998;58:2520-2523.
23. Zurawel RH, Chiappa SA, Allen C, et al. Sporadic medulloblastomas contain oncogenic beta-catenin mutations. Cancer Res 1998;58:896-899.
24. Chan EF, Gat U, McNiff JM, et al. A common human skin tumour is caused by activating mutations in betacatenin. Nat Genet 1999;21:410-413.
25. Garcia-Rostan G, Tallini G, Herrero A, et al. Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma. Cancer Res 1999;59:1811-1815.
26. Tejpar S, Nollet F, Li C, et al. Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor). Oncogene 1999;18:6615-6620.